Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 May 2023, including: novel Bristol Myers Squibb Company drug shows promise in IPF; Novo Nordisk A/S’s oral semaglutide compares well with injectable in weight loss; Teva Pharmaceutical Industries Ltd. looks to innovative brands to return to growth; US setback for Intercept Pharmaceuticals, Inc.’s NASH drug; and India’s improving environment for clinical trials.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode: 

(Also see "BMS Trumpets Breakthrough For Phase III-Bound IPF Drug" - Scrip, 23 May, 2023.)

(Also see "Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III" - Scrip, 22 May, 2023.)

(Also see "Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy" - Scrip, 18 May, 2023.)

(Also see "What Does The Negative FDA Review For Intercept’s OCA Hold For Other NASH Drugs?" - Scrip, 23 May, 2023.)

(Also see "India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change" - Scrip, 22 May, 2023.)

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel